Jazz acquires rights to experimental PTSD drug from SpringWorks in deal valued at up to $410M
October 26, 2020 at 10:00 AM EDT
The deal includes an upfront payment of $35 million.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|